Description
Vilon (Lys-Glu) is a synthetic dipeptide of the Khavinson bioregulator class - one of the shortest and simplest peptides of the class. The substance was developed at the St. Petersburg Institute with research focus on age-related aging markers and immune function.
Per study reports Vilon modulates gene expression in multiple tissues via the Khavinson epigenetic mechanism. Preclinical studies describe effects on lymphocyte function, general aging markers and lifespan-extension indicators in animal models.
In Khavinson’s long-term aging studies Vilon together with Epitalon was described as one of the primary lifespan-extension candidates - in mouse studies documented extension of median lifespan was reported. International replication remains limited.
Typical application is subcutaneous in 10-20 day courses two to three times per year.
You can order Vilon as lyophilized peptide in 10-pack at 20mg per vial.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Vilon is classified as very mild in the available literature and is among the most well tolerated compounds of the Khavinson bioregulator class. In the available preclinical and limited human studies, no relevant toxic effects have been documented.
Observed in research and reports:
- Injection site: mild redness or transient irritation with subcutaneous use is the most common observation. The dipeptide is one of the simplest of the class and is considered low-reactivity.
- Very thin human data: the data base consists almost entirely of small, Russian-language studies from the Khavinson environment. International replication remains limited. Robust long-term safety data in humans do not exist.
- Course-based pattern: the use described occurs in short 10-20 day courses. No data exist on the safety profile of continuous administration.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Effect of vilon on biological age and lifespan in mice - Bulletin of Experimental Biology and Medicine 2000, Khavinson et al: pivotal Vilon study with documented extension of median lifespan in CBA mice.
- Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice - Mechanisms of Ageing and Development 2001, Anisimov et al: Vilon (Lys-Glu) and Epitalon on aging biomarkers and tumor incidence.
- Comparison of the Effects of KE and AED Peptides on Functional Activity of Human Skin Fibroblasts during Their Replicative Aging - Bulletin of Experimental Biology and Medicine 2020, Fridman et al: KE peptide (Vilon sequence) reduces inflammatory markers and stimulates sirtuin-6 in aging cells.
- Age-related molecular aspects of immunomodulating activity of peptides in the spleen - Advances in Gerontology 2014, Chervyakova et al: immunomodulatory action of short peptides including Vilon in lymphoid tissue.
- Peptide bioregulation of aging: results and prospects - Biogerontology 2009, Anisimov and Khavinson: overview review with Vilon as a central geroprotector candidate.
